Background. It has been determined that the chemokine receptor CXCR4 and its ligand stromal cell-derived factor-1 (SDF-1) regulate several key processes in a wide variety of cancers. However, the function and mechanism of the SDF-1/CXCR4 system in the metastasis of colorectal cancer remain controversial. Methods. Immunohistochemistry was performed to examine quantitatively the expression of CXCR4 in 40 human samples of colorectal cancer and liver metastasis. The functions of SDF-1 on HCT116 colon cancer cells were investigated in vitro. We subcutaneously inoculated HCT116 cells with hepatic stellate cells (HSCs) expressing SDF-1. The CXCR4 inhibitor AMD3100 was tested in vitro and in vivo. Results. By quantitatively counting the number of cells, it was shown that there are more CXCR4-positive cells at the metastatic site in the liver compared with the primary sites. We demonstrated the effect of SDF-1 on the invasion and antiapoptosis of HCT116 cells in vitro. In mouse experiment of liver metastasis, intraperitoneal administration of AMD3100 blocked the metastatic potential of HCT116 cells. Furthermore, we found that a-smooth muscle actin (a-SMA)-positive myofibroblasts derived from HSCs, surrounding the liver metastasis foci, secreted SDF-1. The subcutaneous inoculation of HCT116 cells with HSCs promoted the tumor initiation in nude mice, indicating the importance of the direct interaction between these cells in vivo. Conclusion. These results suggest that HSCs play important role in liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis and provide preclinical evidence that blockade of the axis is a target for antimetastasis therapy.
Survival in colorectal cancer is delineated by local recurrence and lymphatic and hematogenous dissemination. 1, 2 Thus one of the most important keys to improving the prognosis of colorectal cancer is to clarify the mechanism of metastasis and plan a new strategy for metastasis or dissemination. The relationship between chemokines or their receptors and metastasis of various cancers has been pointed out previously. [3] [4] [5] [6] [7] [8] [9] The expression of the chemokine receptor CXCR4 in clinical samples is associated with the risk for recurrence and poor survival in colorectal cancers. 10 Another study showed by immunohistochemistry of CXCR4 that its overexpression strongly predicts early relapse of colorectal cancer. 11, 12 However, the evaluations for the expression of CXCR4 have been qualitative, i.e., positive or negative, weak, medium or strong.
CXCR4 and its ligand SDF-1 have been identified as contributing metastatic factors in numerous cancers in several mouse experimental studies. Zeelenberg et al. provided compelling in vivo data in murine models to implicate chemokine receptors in the metastatic progression of cancers to the liver. They describe that CXCR4 is required for outgrowth of colon cancer metastasis, not for initial migration. 6 On the other hand, in some types of cancer, activation of CXCR4 stimulated directed migration and invasion of cancer cells towards a SDF-1 gradient. SDF-1 can also stimulate cancer cell proliferation or survival under suboptimal conditions. These chemokine actions may allow tumor cells to grow at distant sites. The mechanism of these actions remains to be examined in detail during the process of liver metastasis of colorectal cancer.
In this study, we first quantitatively evaluate the expression of CXCR4 in human specimens from primary and metastatic colorectal cancer by immunohistochemistry based on the novel criteria for the positivity of CXCR4. We next reveal the cells secreting SDF-1 in the liver, and study the direct interaction between the cells and colon cancer cells in the mouse model. Finally we examine whether the specific CXCR4 antagonist AMD3100 is able to reduce hepatic tumor formation in metastasis mouse experiments to demonstrate that SDF-1/CXCR4 axis is a promising new target for antimetastatic therapy.
MATERIALS AND METHODS

Patients
A total of 40 patients who underwent surgical resection for colorectal cancer and liver metastasis were selected from our institutional database (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) . Tissue samples of tumors were taken during colectomy and hepatectomy from untreated patients of colorectal carcinoma. Histologic diagnosis was confirmed for each specimen. Written informed consent for molecular analysis of surgical samples was obtained from each patient, and the protocol was approved by the ethical committee of Kyoto University.
Cell Lines
Human colon cancer cell line HCT116 and human stellate cell line LI90 were maintained in Dulbecco's modified Eagle's medium (DMEM, Wako, Osaka, Japan) with 10% fetal bovine serum (FBS; Thermo Trace Ltd., Melbourne, Australia).
Immunohistochemistry
Immunohistochemistry was performed to examine the expression of CXCR4 in colorectal cancer and liver metastasis. Surgical specimens of primary colorectal and metastatic hepatic tumor were routinely fixed in formalin and embedded in paraffin, and were sectioned (4 lm). The sections were immunostained using a TSAsystem (PerkinElmer LAS, Boston, MA). They were deparaffinized with xylene and dehydrated with ethanol, and were treated with 0.1% w/v trypsin (Trypsin 250, DIFCO Becton Dickinson) in 0.1% w/v CaCl 2 /2H 2 O, pH 7.8 at 37°C for 20 min for antigen retrieval. Following preincubation with hydrogen peroxide, DAKO Biotin Blocking System (Dako, Glostrup, Denmark), and blocking buffer in TSA kit, the sections were incubated overnight at 4°C with a mouse monoclonal antihuman CXCR4 (12G5) antibody (R&D System, Minneapolis, MN) at a dilution of 1:300. After incubation with the secondary antibody (rabbit anti-mouse biotinylated; dilution 1:200, DAKO), the avidin-biotin complex of the TSA system was added to the sections and enzyme activity was visualized with diaminobenzidine (DAKO). Hematoxylin was used for counterstaining. Immunostaining for a-SMA (DAKO; dilution 1:500) and SDF-1 (R&D; dilution 1:300) around the liver metastasis was performed in the same manner.
To investigate the number of CXCR4-positive cells in the specimens, we first chose three arbitrary sites under the microscope (409) and counted the cells in a 4 9 10 4 lm 2 region. We then counted the number of CXCR4-positive cells within the region, and calculated its proportion among cancer cells.
RNA Isolation and Reverse-Transcription PCR
Total RNA was isolated from cell pellets using the RNeasy Kit (QIAGEN Sciences, MD) according to the manufacturer's recommendations. Complementary DNA (cDNA) was generated from 1 lg total RNA by reverse transcription using SuperScript TM II Reverse Transcriptase (Invitrogen, Carlbad, CA). One microliter of cDNA was used as a template for the specific polymerase chain reactions (PCRs) for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), CXCR4, and SDF-1. Fifteen microliters of the products were run on a 2% agarose gel, stained by ethidium bromide, and analyzed under ultraviolet (UV) light. The RNA expression level of SDF-1 and CXCR4 between HCT116 and LI90 was normalized to GAPDH levels using Discovery Series Software, Quantity One version 4.6.7 (BioRad Laboratories, Inc., USA).
Proliferation Assay
HCT116 cells (1 9 10 4 ) were cultured in 96-well flatbottomed plates in quadruplicate and allowed to adhere overnight. The media was then replaced with DMEM supplemented with 1% FBS ± 100 ng/ml SDF-1. The proliferative activity was determined 3 days after the beginning of SDF-1 stimulation by WST-8 colorimetric assay (Boehringer, Mannheim) using a microtiter plate reader (Bio-Tek Instruments) at 450 nm (a reference wavelength was subtracted at 600 nm). The background control (blank) was obtained by adding the same volume of culture medium (100 ll) and WST-8 (10 ll) as used in the experimental wells. When indicated, AMD3100 (10 lg/ml) (Sigma, St. Louis, MO), a specific CXCR4 antagonist, was added to the HCT116 cells for 5 min before SDF-1 stimulation and during the stimulation.
Invasion Assay
Invasion activity was determined by a Matrigel invasion chamber assay. HCT116 cells (1 9 10 5 ) were seeded onto the top chamber of a 24-well micropore polycarbonate membrane filter with 8-lm pores (Becton Dickinson Labware, Lincoln Park, NJ), and the bottom chamber was filled with 100 ng/ml SDF-1 in Ham's F12/Roswell Park Memorial Institute (RPMI) 1640 containing 10% of FBS as a chemoattractant. After 20 h incubation in a 5% CO 2 humidified incubator at 37°C, the membranes were fixed and stained with hematoxylin. Invasion was quantified by counting all the cells that had invaded through the membrane under a light microscope.
Apoptosis Assay
HCT116 cells were incubated in triplicate in serum containing 10% FBS, with or without hydrogen peroxide and 100 ng/ml SDF-1. Viable cells were counted 3 days after the beginning of hydrogen peroxide stimulation by trypan blue dye exclusion method. At least three sets of experiments were performed for each set.
ELISA
The concentrations of SDF-1 in the culture supernatants of mouse HSCs were measured by enzyme-linked immunosorbent assay (ELISA) kits (BioSource, Camarillo, CA). Mouse HSCs were isolated from 8-week-old BALB/c mice by in situ collagenase (from Clostridium histolyticum type I; Wako), perfusion and differential centrifugation on Nycodentz (Nycomed Pharma AS, Oslo, Norway) density gradients as previously described, and were cultured in DMEM supplemented with 10% FBS. 13, 14 The purity checks of these primary HSCs after isolation were morphologically confirmed by the presence/absence of fat drops using an optical microscope.
14 Purity rates of HSCs isolation were [95% in all the experiments.
In Vivo Experiments
Five-to six-week-old, male KSN Slc (nu/nu) mice were obtained from Japan SLC (Hamamatsu, Japan) and maintained in our specific pathogen-free animal facility. All animals were kept according to the Animal Protection Guidelines of Kyoto University. All protocols for animal use and euthanasia were reviewed and approved by the Institute of Laboratory Animals, Graduate School of Medicine, Kyoto University. HCT116 (5 9 10 6 ) suspended in 100 ll phosphate-buffered saline (PBS) were injected into the spleen of the mice under anesthesia. They were given intraperitoneal injections of 10 mg/kg AMD3100 (Sigma, St. Louis, MO) or PBS daily from 1 day before beginning the injection of cancer cells. Autopsies were performed after 2 weeks. The livers of HCT116 injected mice were surgically removed for microscopic observation. The extracted liver was embedded in optimum cutting temperature (OCT) compound for frozen sections. The sections were stained by hematoxylin and eosin (H&E) and examined microscopically for the presence of liver metastasis.
We subcutaneously inoculated various amounts of HCT116 cells with or without 1 9 10 5 LI90 cells into the back of nude mice. After 2 weeks, we observed whether subcutaneous tumors were formed or not.
Statistics
Statistical significance was determined by t-test with Bonferroni correction in immunohistochemistry for CXCR4, Student's t-test for in vitro assays, and Fisher's exact test for in vivo assays. P values less than 0.05 were considered significant.
RESULTS
Quantitative Evaluation of CXCR4-Positive Cells in Primary and Metastatic Colorectal Tumors in Human Samples
The degree of CXCR4 expression in colorectal cancer is known to be associated with liver metastasis, and its expression level has been qualitatively evaluated in previous reports. Here we assessed the proportion of CXCR4-positive colorectal cancer cells in human tissue samples to quantitatively evaluate the expression of CXCR4. We carried out immunostaining for CXCR4 in the samples obtained from 40 primary colorectal carcinomas (Fig. 1a,  b ) and 20 liver metastases (Fig. 1c) . The representative stains identified the expression of CXCR4 in the cytoplasm and/or the cell membrane of the cancer cells. The primary cancers expressed CXCR4 heterogeneously in various patterns, while its expression was almost homogeneous in the liver metastases. We counted the number of all cancer cells and CXCR4-positive cancer cells in each arbitrary area, and calculated the proportion of CXCR4-positive cancer cells. The proportion of CXCR4 expression in the primary tumors with liver metastasis was significantly higher than in those without liver metastasis (mean, 55.1% versus 40%; P \ 0.05), compatible with the previous reports (Fig. 1d) . Interestingly, in the 20 paired-tissue specimens from patients with primary and metastatic lesions, CXCR4 expression was higher in liver metastasis than in paired primary tumor (mean, 79% versus 55.1%; P \ 0.05) (Fig. 1e) . These findings suggest that the CXCR4-positive cancer cells may selectively proliferate or may be more likely to survive in the liver.
SDF-1 Promotes Invasion and Survival of Human Colon Cancer Cells
In order to understand the biological role of CXCR4 in colon cancer cells, we first examined the effect of SDF-1 on cell proliferation of HCT116 colon cancer cells (Fig. 2a) . However, SDF-1 failed to enhance the proliferation of HCT116 cells. We then performed Matrigel invasion assays to demonstrate the functional role of CXCR4 under the stimulation of SDF-1 (Fig. 2b) . The number of invading HCT116 cells after stimulation with SDF-1 was significantly greater than untreated controls (P \ 0.05). The incubation of the cells with AMD3100 blocked the activity of invasion by 18.5% (P \ 0.05). Finally, we investigated the impact of SDF-1 on the apoptosis of HCT116 cells by hydrogen peroxide (Fig. 2c) . Consequently, HCT116 cells became resistant to apoptosis by the stimulation with SDF-1, and AMD3100 reduced this ability of SDF-1-dependent antiapoptosis. These findings suggest that the increase of CXCR4-positive cells in metastatic sites may be caused by the enhanced invasion and antiapoptosis ability, but not by the increased proliferation, of colon cancer cells through SDF-1.
AMD3100 Inhibits Liver Metastasis of Colon Cancer Cells In Vivo
It is known that injection of HCT116 cells into the spleen of nude mice results in the formation of hepatic tumors (Fig. 3a-d) . 15, 16 We tested the inhibitory effect of AMD3100 on the development of tumors in the liver (Fig. 3a, c) . Tumor formation in the liver macroscopically and microscopically was significantly (P \ 0.05) suppressed by the treatment with AMD3100 ( Table 1 ). The weight of the livers was significantly decreased by the administration of AMD3100 (Fig. 3e) . These findings suggested that the function of SDF-1/CXCR4 on colon cancer cells was closely related to liver metastasis in vivo.
Activated HSCs Secrete SDF-1 In Vitro
We observed a cell population positive for a-SMA, identified as myofibroblasts, surrounding metastatic hepatic tumors in human specimens (Fig. 4a-d) . 17, 18 Carcinomaassociated fibroblasts (CAFs) in cancer tissues, which exhibit the traits of myofibroblasts, have been recently reported to play a central role in promoting tumor growth by secreting SDF-1. 19 On the other hand, the features of the response of HSCs to hepatic tissue injury are phenotypical and functional changes, a process called activation, including cell proliferation and transforming star-shaped cells rich in vitamin A to vitamin A-deficient cells of myofibroblast-like appearance displaying a-SMA. 20 It is thus thought that a-SMA-positive myofibroblasts in the liver metastasis are derived from HSCs. Interestingly, the expression of SDF-1 in developing mesenteries appears in mesenchymal cells adjacent to endothelial cells. 21 In this study we found that the subset of fibroblast-like cells positive for a-SMA (as indicated by arrows in Fig. 4c ) were also positive for SDF-1 (as indicated by arrow heads, Fig. 4d ) in tumor stroma. Accordingly, we determined that HSCs could be the source of SDF-1 in the liver metastasis. We then measured the concentration of SDF-1 in the culture supernatant of quiescent HSCs and activated HSCs obtained from mouse liver by ELISA assay (Fig. 4e) . The concentration of SDF-1 derived from activated HSCs was significantly higher than quiescent HSCs (P \ 0.05). ) suspended in 100 ll PBS were injected into the spleen of the mice. They were given intraperitoneal injections of 10 mg/kg AMD3100 or PBS daily from 1 day before beginning the injection of cancer cells, and were sacrificed after 2 weeks. Macroscopic images (a, b) and H&E staining of livers from nude mice (c, d). The metastatic tumors (arrows and framed by dashed line) were found with PBS (a, c), but no significant tumors were observed with AMD3100 (b, d). e Reduction of the liver weight by AMD3100 administration Taken together, activated form of HSCs may possibly play a role in the survival and invasion of colorectal cancer cells at metastatic sites by secreting SDF-1, to establish liver metastatic tumors.
HSCs Help Human Colon Cancer Cells to Form the Subcutaneous Tumors in Nude Mouse
To investigate the direct interaction between colon cancer cells and HSCs, we subcutaneously inoculated different amounts of HCT116 cells with LI90 cells, a cell line that exhibits characteristics comparable to those of HSCs, in nude mice. LI90 cells were confirmed to secrete SDF-1 by reverse-transcription PCR (RT-PCR) (Fig. 5a, b) . Subcutaneous tumorigenesis in nude mouse required at least 1 9 10 6 HCT116 cells (Table 2) . It is generally known that a certain number of cancer cells are required to form a tumor mass, and when the total number is smaller, outgrowth of cancer cells cannot be achieved simply by colonizing at metastatic sites. Surprisingly, however, HCT116 cells could form the subcutaneous tumors with fewer cells in the presence of 1 9 10 5 LI90 cells (Table 2 ). This phenomenon may implicate the outgrowth of a few cancer cells in the metastatic site by the help of LI90 cells. The tumor formation was suppressed by intraperitoneal administration of AMD3100. These results indicate that there is direct interaction between colon cancer cells and HSCs in vivo, mediated by SDF-1/CXCR4 axis. Furthermore, we performed subcutaneous injection of HCT116 cells that had been stimulated by the conditioned medium LI90 cells or by SDF-1; however, the similar results were not reproduced (data not shown). The initial stimulation of HCT116 cells by SDF-1 or the secreted factors from LI90 cells was insufficient for the enhancement.
DISCUSSION
Although metastasis is the main cause of cancer death in the Western world, the mechanisms of organ-specific metastasis are largely unknown. Recent evidence suggests an important role for SDF-1 and CXCR4 in the metastatic homing and establishment of tumor cells. 6, [10] [11] [12] [22] [23] [24] In this study, we have shown that the number of CXCR4-positive colon cancer cells was increased at the metastatic site by immunohistochemistry based on the novel criteria for the positivity of CXCR4. This observed increase may be because CXCR4-positive cancer cells selectively proliferate or Experimental intrasplenic liver metastatic assays were performed to determine the effect of the specific CXCR4 antagonist AMD3100. AMD3100 (10 mg/kg) or PBS as a control was administered intraperitoneally once a day for 14 days and metastatic lesions were examined. Statistical analysis between the treatment groups was made by Fisher's exact test * P \ 0.05, compared with PBS survive in the metastatic site. In breast cancer, it was indicated that CXCR4 might promote metastasis by acting directly on tumor cell migration and invasion. 4 RNA interference (RNAi) experiments indicated that CXCR4 was required to initiate proliferation and/or promote survival of breast cancer cells in vivo.
25 CXCR4-deficient CT-26 colorectal cancer cells resulted in fewer lung and liver metastases, but colonized the lungs to the same extent as control cells; they survived but did not proliferate. 6 It was also demonstrated that CXCR3 played a critical role in colon cancer metastasis to lymph nodes by inducing diverse cellular effect such as cytoskeletal rearrangement, migration, invasion, matrix metalloproteinase (MMP)-2/9, expression, and cell survival through activation of extracellular signalregulated kinase (ERK)1/2 and Akt/protein kinases B (PKB) pathways. 26 Interestingly, we have revealed that the formation of liver metastasis was introduced by invasion and antiapoptosis but not by proliferation of cancer cells with the stimulation of SDF-1 in vitro. The role of CXCR4 in the proliferation of cancer cells was controversial. Indeed, many previous reports have shown that SDF-1 enhanced proliferation in colon and gastric cancer cells. On the other hand, some reports have denied the effect. The method of the proliferation assay in our study using the seeding medium with 1% FBS allowed the antiapoptosis effect to be ignored. Our results rather support the conclusion that tumor in metastatic site could form because CXCR4-positive cancer cells selectively survive. Importantly, in our study, colorectal cancer cells could form subcutaneous tumors with small numbers of cells by co-injection of HSCs. This phenomenon may indicate that liver metastasis could be formed with the help of HSCs secreting SDF-1. In other words, the role of SDF-1/CXCR4 axis may provide a potential of tumor initiation for cancer cells at metastatic sites. Indeed, it was demonstrated that a subpopulation of migrating CD133
? CXCR4 ? cancer stem cells was essential for tumor metastasis in pancreatic adenocarcinoma. 27 Constitutive secretion of SDF-1 by bone marrow stromal cells is a major source for SDF-1 in the adult. 28 In malignancies, CAFs, but not normal fibroblasts, stimulate tumor progression by SDF-1 secretion.
19 SDF-1 is highly expressed by stromal fibroblasts within primary breast cancer or at metastatic site. 4, 29 In this study, we found that SDF-1 in liver was secreted by activated HSCs. Furthermore, we have shown that LI90 cells promoted tumor formation of HCT116 cells. Colon cancer cells may therefore drift ashore to the liver, where activated HSCs secrete SDF-1 and promote tumor formation. So, when or how are HSCs activated during the process of metastasis? It has been previously reported that HSCs were activated by various stimuli, i.e., platelet-derived growth factor-AB, hepatocyte growth factor, and transforming growth factorb, and underwent transformation into myofibroblasts when colon cancer cells migrated into the liver, by mouse experiments. 30 HSCs and colon cancer cells could activate each other to form the metastasis foci in the liver.
To investigate the possibility of selective survival of CXCR4-positive cancer cells in metastatic sites, we ) were subcutaneously injected into the back of nude mice together with or without 1 9 10 5 LI90 cells. After 2 weeks of implantation, we checked for the presence of subcutaneous tumors. AMD3100 was intraperitoneally administrated to mice with co-injection of 1 9 10 3 HCT116 cells and 1 9 10 5 LI90 cells separated HCT116 cells into CXCR4 ? and CXCR4 -cells by fluorescent-activated cell sorting (FACS) isolation and studied whether hepatic tumors could be formed by intrasplenic injection of CXCR4
? and CXCR4 -cells in nude mice. Unexpectedly, we did not observe significant differences between CXCR4
? and CXCR4 -colon cancer cells (unpublished data). Therefore, it is thought that cancer cells are stimulated to express CXCR4 by some factors in the liver. For example, hypoxia, a well-known trigger for metastasis, induces CXCR4 expression. 31 Downregulation of von Hippel-Lindau (VHL) tumor suppressor proteins (pVHL19 and pVHL30) leads to upregulation of CXCR4 and SDF-1 in clear cell renal cell carcinoma. 32 The significant change of CXCR4 expression of CT-26 carcinoma cells has already been confirmed by FACS sorting from a lung cell suspension in an experiment on lung metastasis. 6 The importance of the SDF-1/CXCR4 axis for colorectal cancer metastasis was directly demonstrated in our study through the antimetastatic activity of AMD3100. This antagonist of CXCR4 blocked the metastatic potential of HCT116 cells in vivo. AMD3100 is expected to become an effective treatment for inhibition of metastasis and, on the other hand, the phase III program for stem cell transplant in non-Hodgkin's lymphoma or multiple myeloma patients who are given AMD3100 in combination with the standard agent, granulocyte-colony stimulating factor, was planned by AnorMED Inc. in the USA (bought up by Millennium Inc., http://www.millennium.com/). Furthermore, a specific and reversible CXCR4 inhibitor, AMD070, which is a derivative of AMD3100 and a next-generation oral CXCR4 antagonist, has been developed and is currently being studied in phase II clinical trials (ClinicalTrials.gov-A study of AMD11070 in HIV-Infected Patients Carrying X4-Tropic Virus., http://www.clinicaltrials.gov/ct/show/ NCT00361101). A new treatment strategy will be established by trying to administer these agents to colorectal cancer patients and examining the antimetastatic effect. Needless to say, experimental therapeutic studies remain to be done before clinical trials.
